

<b>Notice of References Cited</b>	Application/Control No.	Applicant(s)/Patent Under Reexamination
	10/009,436	CARMELIET ET AL.
	Examiner	Art Unit
	David Montanari	1632

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Hayes TJ, Safety Considerations of recombinant protein therapy: introductory comments. 1997, Clinical Immunology and Immunopathology, Vol. 83, pgs. 1-4.□□
	V	Brown LR, Commercial challenges of protein drug delivery, 2005, Expert Opinion, Vol. 2, pgs. 29-42.
	W	Melaragno MG, Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt, 2004, J. of Molecular and Cellular Cardiology, Vol. 37, pgs. 881-887.
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.